- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT02693535
TAPUR : Test de l'utilisation de médicaments approuvés par la Food and Drug Administration (FDA) qui ciblent une anomalie spécifique dans un gène tumoral chez les personnes atteintes d'un cancer à un stade avancé (TAPUR)
Étude du registre d'utilisation des agents ciblés et du profilage (TAPUR)
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug.
NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact TAPUR@asco.org, or if a patient, your nearest participating TAPUR site (see participating centers).
********************************************************************
Results in publication or poster presentation format are posted as they become available for individual cohorts at www.tapur.org/news. The results may be accessed at any time. All results will be made available on clinicaltrials.gov at the end of the study. Indexing of available results on PubMed is in progress.
********************************************************************
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
- Médicament: Sunitinib (CLOSED TO ENROLLMENT)
- Médicament: Trastuzumab and Pertuzumab (CLOSED TO ENROLLMENT)
- Médicament: Vemurafenib and Cobimetinib (CLOSED TO ENROLLMENT)
- Médicament: Olaparib (CLOSED TO ENROLLMENT)
- Médicament: Nivolumab and Ipilimumab (CLOSED TO ENROLLMENT)
- Médicament: Abemaciclib (CLOSED TO ENROLLMENT)
- Médicament: Talazoparib (CLOSED TO ENROLLMENT)
- Médicament: Atezolizumab and Talazoparib (CLOSED TO ENROLLMENT)
- Médicament: Tucatinib plus Trastuzumab Subcutaneous (SC) (CLOSED TO ENROLLMENT)
- Médicament: Futibatinib
- Médicament: Dabrafenib plus Trametinib
- Médicament: Fam-Trastuzumab Deruxtecan-Nxki (TDxD)
Description détaillée
The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a non-randomized clinical trial that aims to describe the safety and efficacy of commercially available, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic variant. TAPUR will study Food and Drug Administration (FDA)-approved targeted therapies that are contributed by collaborating pharmaceutical companies, catalogue the choice of molecular profiling test by clinical oncologists and develop hypotheses for additional clinical trials.
Type d'étude
Inscription (Estimé)
Phase
- Phase 2
Contacts et emplacements
Coordonnées de l'étude
- Nom: Laurie Smith, MA
- Numéro de téléphone: www.tapur.org
- E-mail: tapur@asco.org
Lieux d'étude
-
-
Puerto Rico
-
Cayey, Puerto Rico, Porto Rico, 00737
- Recrutement
- PanOncology Trials
-
Contact:
- Natalia Ortiz
- Numéro de téléphone: 787-407-3333
- E-mail: natalia.ortiz@panoncologytrials.com
-
Chercheur principal:
- Maria Cruz Correa, MD
-
Dorado, Puerto Rico, Porto Rico, 00646
- Recrutement
- PanOncology Trials
-
Contact:
- Natalia Ortiz
- Numéro de téléphone: 787-407-3333
- E-mail: natalia.ortiz@panoncologytrials.com
-
Chercheur principal:
- Maria Cruz Correa, MD
-
Manati, Puerto Rico, Porto Rico, 00674
- Recrutement
- PanOncology Trials
-
Contact:
- Natalia Ortiz
- Numéro de téléphone: 787-407-3333
- E-mail: natalia.ortiz@panoncologytrials.com
-
Chercheur principal:
- Maria Crus Correa, MD
-
Mayagüez, Puerto Rico, Porto Rico, 00680
- Recrutement
- PanOncology Trials
-
Contact:
- Natalia Ortiz
- Numéro de téléphone: 787-407-3333
- E-mail: natalia.ortiz@panoncologytrials.com
-
Chercheur principal:
- Maria Cruz Correa, MD
-
Ponce, Puerto Rico, Porto Rico, 00730
- Recrutement
- PanOncology Trials
-
Contact:
- Natalia Ortiz
- Numéro de téléphone: 787-407-3333
- E-mail: natalia.ortiz@panoncologytrials.com
-
Chercheur principal:
- Maria Cruz Correa, MD
-
San Juan, Puerto Rico, Porto Rico, 00909
- Recrutement
- PanOncology Trials
-
Contact:
- Natalia Ortiz
- Numéro de téléphone: 787-407-3333
- E-mail: natalia.ortiz@panoncologytrials.com
-
Chercheur principal:
- Maria Cruz Correa, MD
-
San Juan, Puerto Rico, Porto Rico, 00935
- Recrutement
- PanOncology Trials
-
Contact:
- Natalia Ortiz
- Numéro de téléphone: 787-407-3333
- E-mail: natalia.ortiz@panoncologytrials.com
-
Chercheur principal:
- Maria Cruz Correa, MD
-
-
-
-
Alabama
-
Birmingham, Alabama, États-Unis, 35294
- Recrutement
- University of Alabama at Birmingham Comprehensive Cancer Center
-
Chercheur principal:
- Mehmet Akce, MD
-
Contact:
- Kun Yuan
- Numéro de téléphone: 205-644-2584
- E-mail: kunyuan@uabmc.edu
-
-
Arizona
-
Phoenix, Arizona, États-Unis, 85338
- Recrutement
- Cancer Treatment Centers of America-Phoenix
-
Chercheur principal:
- Sagun Shrestha, MD
-
Contact:
- Alex Lizzul
- Numéro de téléphone: 602-872-5654
- E-mail: alizzul@coh.org
-
-
California
-
Auburn, California, États-Unis, 95602
- Recrutement
- Sutter Auburn
-
Contact:
- Kirsten Babski
- Numéro de téléphone: 916-878-4990
- E-mail: BabskiK@sutterhealth.org
-
Chercheur principal:
- Nitin Rohatgi, MD
-
Berkeley, California, États-Unis, 94705
- Recrutement
- Sutter Alta Bates
-
Contact:
- Christopher Tang
- Numéro de téléphone: 510-204-3428
- E-mail: Christopher.Tang@sutterhealth.org
-
Chercheur principal:
- Nitin Rohatgi, MD
-
Los Angeles, California, États-Unis, 90025
- Recrutement
- The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate
-
Contact:
- Teri Mata
- Numéro de téléphone: 310-231-2115
- E-mail: tmata@theangelesclinic.org
-
Chercheur principal:
- Omid Hamid, MD
-
Oakland, California, États-Unis, 94611
- Recrutement
- Kaiser Permanente - Oakland Medical Center
-
Contact:
- Desiree Goldstein
- E-mail: desiree.goldstein@kp.org
-
Chercheur principal:
- Jennifer M Suga, MD
-
Palo Alto, California, États-Unis, 94301
- Recrutement
- Sutter Palo Alto Medical Foundation: Palo Alto
-
Contact:
- E-mail: clinicaltrials@pamf.org
-
Roseville, California, États-Unis, 95661
- Recrutement
- Kaiser Permanente - Roseville Medical Center
-
Contact:
- Desiree Goldstein
- E-mail: desiree.goldstein@kp.org
-
Chercheur principal:
- Jennifer M Suga, MD
-
Roseville, California, États-Unis, 95661
- Recrutement
- Sutter Roseville
-
Contact:
- Kirsten Babski
- Numéro de téléphone: 916-878-4990
- E-mail: BabskiK@sutterhealth.org
-
Chercheur principal:
- Nitin Rohatgi, MD
-
Sacramento, California, États-Unis, 95814
- Recrutement
- Kaiser Permanente - Sacramento Medical Center
-
Contact:
- Desiree Goldstein
- E-mail: desiree.goldstein@kp.org
-
Chercheur principal:
- Jennifer M Suga, MD
-
Sacramento, California, États-Unis, 95816
- Recrutement
- Sutter Sacramento
-
Contact:
- E-mail: SIMR@sutterhealth.org
-
Chercheur principal:
- Nitin Rohatgi, MD
-
San Francisco, California, États-Unis, 94115
- Recrutement
- California Pacific Medical Center Research Institute
-
Contact:
- Numéro de téléphone: 415-600-1654
- E-mail: clinicalresearch@sutterhealth.org
-
Chercheur principal:
- Nitin Rohatgi, MD
-
San Francisco, California, États-Unis, 94080
- Recrutement
- Kaiser Permanente - South San Francisco Medical Center
-
Contact:
- Desiree Goldstein
- E-mail: desiree.goldstein@kp.org
-
Chercheur principal:
- Jennifer M Suga, MD
-
San Francisco, California, États-Unis, 94115
- Recrutement
- Kaiser Permanente - San Francisco Medical Center
-
Contact:
- Desiree Goldstein
- E-mail: desiree.goldstein@kp.org
-
Chercheur principal:
- Jennifer M Suga, MD
-
San Francisco, California, États-Unis, 94115
- Recrutement
- Sutter Cancer Research Consortium
-
Contact:
- Laurel Brechtel
- Numéro de téléphone: 415-600-1654
- E-mail: BrechtLa@cpmcri.org
-
Chercheur principal:
- Stacy D'Andre, MD
-
San Jose, California, États-Unis, 95119
- Recrutement
- Kaiser Permanente - San Jose Medical Center
-
Contact:
- Desiree Goldstein
- E-mail: desiree.goldstein@kp.org
-
Chercheur principal:
- Jennifer M Suga, MD
-
San Leandro, California, États-Unis, 94577
- Recrutement
- Kaiser Permanente - San Leandro Medical Center
-
Contact:
- Desiree Goldstein
- E-mail: desiree.goldstein@kp.org
-
Chercheur principal:
- Jennifer M Suga, MD
-
Santa Barbara, California, États-Unis, 93105
- Recrutement
- Sutter Sansum Clinic
-
Chercheur principal:
- Nitin Rohatgi, MD
-
Contact:
- Selina Perez
- Numéro de téléphone: 831-458-5837
- E-mail: Selina.Perez@sutterhealth.org
-
Santa Clara, California, États-Unis, 95051
- Recrutement
- Kaiser Permanente - Santa Clara Medical Center
-
Contact:
- Desiree Goldstein
- E-mail: desiree.goldstein@kp.org
-
Chercheur principal:
- Jennifer M Suga, MD
-
Santa Cruz, California, États-Unis, 95065
- Recrutement
- Sutter Palo Alto Medical Foundation: Santa Cruz
-
Contact:
- E-mail: clinicaltrials@pamf.org
-
Santa Cruz, California, États-Unis, 994538
- Recrutement
- Sutter Palo Alto Medical Foundation: Fremont
-
Contact:
- E-mail: clinicaltrials@pamf.org
-
Sunnyvale, California, États-Unis, 94086
- Recrutement
- Sutter Palo Alto Medical Foundation: Sunnyvale
-
Contact:
- E-mail: clinicaltrials@pamf.org
-
Vallejo, California, États-Unis, 94589
- Recrutement
- Kaiser Permanente - Vallejo Medical Center
-
Contact:
- Desiree Goldstein
- E-mail: desiree.goldstein@kp.org
-
Chercheur principal:
- Jennifer M. Suga, MD
-
Walnut Creek, California, États-Unis, 94596
- Recrutement
- Kaiser Permanente - Walnut Creek Medical Center
-
Contact:
- Desiree Goldstein
- E-mail: desiree.goldstein@kp.org
-
Chercheur principal:
- Jennifer M Suga, MD
-
-
Connecticut
-
Bridgeport, Connecticut, États-Unis, 06606
- Recrutement
- Saint Vincent's Medical Center (SVMC)
-
Contact:
- Numéro de téléphone: 860-972-4700
- E-mail: CancerResearchSupport@hhchealth.org
-
Chercheur principal:
- Wylie Hosmer, MD
-
Hartford, Connecticut, États-Unis, 06102
- Recrutement
- Hartford Hospital
-
Contact:
- Numéro de téléphone: 860-972-4700
- E-mail: CancerResearchSupport@hhchealth.org
-
Chercheur principal:
- Wylie Hosmer, MD
-
Meriden, Connecticut, États-Unis, 06451
- Recrutement
- Midstate Medical Center (MSMC)
-
Contact:
- Numéro de téléphone: 860-972-4700
- E-mail: CancerResearchSupport@hhchealth.org
-
Chercheur principal:
- Wylie Hosmer, MD
-
New Britain, Connecticut, États-Unis, 06053
- Recrutement
- The Hospital of Central Connecticut (HOCC) Cancer Center
-
Chercheur principal:
- Wylie Hosmer, MD
-
Contact:
- Numéro de téléphone: 8609724700
- E-mail: CancerResearchSupport@hhchealth.org
-
Norwich, Connecticut, États-Unis, 06360
- Recrutement
- William W. Backus Hospital
-
Contact:
- Numéro de téléphone: 860-972-4700
- E-mail: CancerResearchSupport@hhchealth.org
-
Chercheur principal:
- Wylie Hosmer, MD
-
Torrington, Connecticut, États-Unis, 06790
- Recrutement
- Charlotte Hungerford
-
Contact:
- Numéro de téléphone: 860-972-4700
- E-mail: CancerResearchSupport@hhchealth.org
-
Chercheur principal:
- Wylie Hosmer, MD
-
Willimantic, Connecticut, États-Unis, 06226
- Recrutement
- Windham Hospital (WH)
-
Contact:
- Numéro de téléphone: 860-972-4700
- E-mail: CancerResearchSupport@hhchealth.org
-
Chercheur principal:
- Wylie Hosmer, MD
-
-
Florida
-
Altamonte Springs, Florida, États-Unis, 32701
- Actif, ne recrute pas
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Aventura, Florida, États-Unis, 33180
- Recrutement
- University of Miami/Sylvester Cancer Institute - Aventura
-
Contact:
- Carolina Troche, BS
- Numéro de téléphone: 305-243-1481
- E-mail: cxt582@med.miami.edu
-
Chercheur principal:
- Carmen Calfa, MD
-
Bonita Springs, Florida, États-Unis, 34135
- Actif, ne recrute pas
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Bradenton, Florida, États-Unis, 34211
- Actif, ne recrute pas
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Brandon, Florida, États-Unis, 33511
- Actif, ne recrute pas
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Cape Coral, Florida, États-Unis, 33909
- Actif, ne recrute pas
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Clearwater, Florida, États-Unis, 33761
- Actif, ne recrute pas
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Coral Gables, Florida, États-Unis, 33146
- Recrutement
- University of Miami/Sylvester Cancer Institute - Lennar
-
Contact:
- Carolina Troche, BS
- Numéro de téléphone: 305-243-1481
- E-mail: cxt582@med.miami.edu
-
Chercheur principal:
- Carmen Calfa, MD
-
Deerfield Beach, Florida, États-Unis, 33442
- Recrutement
- University of Miami/Sylvester Cancer Institute - Deerfield Beach
-
Contact:
- Carolina Troche, BS
- Numéro de téléphone: 305-243-1481
- E-mail: cxt582@med.miami.edu
-
Chercheur principal:
- Carmen Calfa, MD
-
Fort Lauderdale, Florida, États-Unis, 33308
- Recrutement
- Holy Cross Hospital
-
Chercheur principal:
- Zdenka Segota, MD
-
Contact:
- Numéro de téléphone: 7347123671
- E-mail: MCRCwebsitecontactform@trinity-health.org
-
Fort Myers, Florida, États-Unis, 33901
- Actif, ne recrute pas
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Fort Myers, Florida, États-Unis, 33905
- Actif, ne recrute pas
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Fort Myers, Florida, États-Unis, 33908
- Actif, ne recrute pas
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Gainesville, Florida, États-Unis, 32610
- Recrutement
- University of Florida Health
-
Chercheur principal:
- Thomas George, MD
-
Contact:
- Anna Kukulka, RN, BSN
- Numéro de téléphone: 352-293-2551
- E-mail: akukulka@ufl.edu
-
Gainesville, Florida, États-Unis, 32605
- Actif, ne recrute pas
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Largo, Florida, États-Unis, 33770
- Actif, ne recrute pas
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Lecanto, Florida, États-Unis, 34461
- Actif, ne recrute pas
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Miami, Florida, États-Unis, 33136
- Recrutement
- University of Miami Sylvester Comprehensive Cancer Center
-
Contact:
- Carolina Troche, BS
- Numéro de téléphone: 305-243-1481
- E-mail: cxt582@med.miami.edu
-
Chercheur principal:
- Carmen Calfa, MD
-
Miami, Florida, États-Unis, 33136
- Recrutement
- University of Miami/Sylvester Cancer Institute - Alex's Place
-
Contact:
- Carolina Troche, BS
- Numéro de téléphone: 305-243-1481
- E-mail: cxt582@med.miami.edu
-
Chercheur principal:
- Carmen Calfa, MD
-
Miami, Florida, États-Unis, 33136
- Recrutement
- University of Miami/Sylvester Cancer Institute - Griffin Cancer Research Building
-
Contact:
- Carolina Troche, BS
- Numéro de téléphone: 305-243-1481
- E-mail: cxt582@med.miami.edu
-
Chercheur principal:
- Carmen Calfa, MD
-
Miami, Florida, États-Unis, 33176
- Recrutement
- University of Miami/Sylvester Cancer Institute - Kendall
-
Contact:
- Carolina Troche, BS
- Numéro de téléphone: 305-243-1481
- E-mail: cxt582@med.miami.edu
-
Chercheur principal:
- Carmen Calfa, MD
-
Miami, Florida, États-Unis, 33181
- Recrutement
- University of Miami/Sylvester Cancer Institute - Sole Mia
-
Contact:
- Carolina Troche, BS
- Numéro de téléphone: 305-243-1481
- E-mail: cxt582@med.miami.edu
-
Chercheur principal:
- Carmen Calfa, MD
-
Naples, Florida, États-Unis, 34102
- Actif, ne recrute pas
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Ocala, Florida, États-Unis, 34474
- Actif, ne recrute pas
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Orange City, Florida, États-Unis, 32763
- Actif, ne recrute pas
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Orlando, Florida, États-Unis, 32806
- Actif, ne recrute pas
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Plantation, Florida, États-Unis, 33324
- Recrutement
- University of Miami/Sylvester Cancer Institute - Plantation
-
Contact:
- Carolina Troche, BS
- Numéro de téléphone: 305-243-1481
- E-mail: cxt582@med.miami.edu
-
Chercheur principal:
- Carmen Calfa, MD
-
Port Charlotte, Florida, États-Unis, 33980
- Actif, ne recrute pas
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Sarasota, Florida, États-Unis, 34236
- Actif, ne recrute pas
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Sarasota, Florida, États-Unis, 34239
- Actif, ne recrute pas
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
St. Petersburg, Florida, États-Unis, 33701
- Actif, ne recrute pas
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Tampa, Florida, États-Unis, 33607
- Actif, ne recrute pas
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Tavares, Florida, États-Unis, 32778
- Actif, ne recrute pas
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
The Villages, Florida, États-Unis, 32159
- Actif, ne recrute pas
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Trinity, Florida, États-Unis, 34655
- Actif, ne recrute pas
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Venice, Florida, États-Unis, 34285
- Actif, ne recrute pas
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Venice, Florida, États-Unis, 34292
- Actif, ne recrute pas
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Winter Park, Florida, États-Unis, 32789
- Actif, ne recrute pas
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
-
Georgia
-
Atlanta, Georgia, États-Unis, 30322
- Recrutement
- Emory University Winship Cancer Institute
-
Chercheur principal:
- Olatunji Alese, MD
-
Contact:
- Krystal Bagley
- Numéro de téléphone: 404-778-8670
- E-mail: krystal.joi.bagley@emory.edu
-
Atlanta, Georgia, États-Unis, 30265
- Recrutement
- Cancer Treatment Centers of America - Atlanta
-
Chercheur principal:
- Bamidele Adesunloye, MD
-
Contact:
- Elizabeth McKoy, RN, BSN
- Numéro de téléphone: 770-400-7177
- E-mail: emckoy@coh.org
-
Savannah, Georgia, États-Unis, 31405
- Recrutement
- Summit Cancer Care
-
Chercheur principal:
- Mark Taylor, MD
-
Contact:
- Stephanie Smith, RN, MSN, OCN
- Numéro de téléphone: 9128195723
- E-mail: smiths1@sjchs.org
-
Savannah, Georgia, États-Unis, 31405
- Recrutement
- Gynecologic Oncology and Surgical Specialists at the Lewis Cancer & Research Pavilion
-
Chercheur principal:
- Mark Taylor, MD
-
Contact:
- Stephanie Smith, RN, MSN, OCN
- Numéro de téléphone: 9128195723
- E-mail: smiths1@sjchs.org
-
Savannah, Georgia, États-Unis, 31405
- Recrutement
- Lewis Cancer & Research Pavilion at the Melanoma, Skin Cancer & Sarcoma Institute
-
Chercheur principal:
- Mark Taylor, MD
-
Contact:
- Stephanie Smith, RN, MSN, OCN
- Numéro de téléphone: 19128195723
- E-mail: smiths1@sjchs.org
-
Savannah, Georgia, États-Unis, 31405
- Recrutement
- Lewis Cancer & Research Pavilion
-
Contact:
- Stephanie Smith, RN, MSN, OCN
- Numéro de téléphone: 912-819-5723
- E-mail: smiths1@sjchs.org
-
Chercheur principal:
- Mark Taylor, MD
-
-
Hawaii
-
Honolulu, Hawaii, États-Unis, 96813
- Recrutement
- The Queen's Medical Center - POB I
-
Chercheur principal:
- Jared Acoba, MD
-
Contact:
- Tim Kelleher
- Numéro de téléphone: 8086918582
- E-mail: tkelleher@queens.org
-
Honolulu, Hawaii, États-Unis, 96813
- Recrutement
- The Queen's Medical Center - Punchbowl
-
Chercheur principal:
- Jared Acoba, MD
-
Contact:
- Tim Kelleher
- Numéro de téléphone: 808 691-8582
- E-mail: tkelleher@queens.org
-
Honolulu, Hawaii, États-Unis, 96817
- Recrutement
- The Queen's Medical Center - Kuakini
-
Chercheur principal:
- Jared Acoba, MD
-
Contact:
- Tim Kelleher
- Numéro de téléphone: 8086918582
- E-mail: tkelleher@queens.org
-
‘Ewa Beach, Hawaii, États-Unis, 96706
- Recrutement
- The Queen's Medical Center - West Oahu
-
Chercheur principal:
- Jared Acoba, MD
-
Contact:
- Tim Kelleher
- Numéro de téléphone: 8086918582
- E-mail: tkelleher@queens.org
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60099
- Recrutement
- Cancer Treatment Centers of America-Chicago
-
Chercheur principal:
- Evan Pisick, MD
-
Contact:
- Office of Clinical Trials
- Numéro de téléphone: 847-731-1777
- E-mail: CHIResearch@coh.org
-
-
Indiana
-
Indianapolis, Indiana, États-Unis, 46250
- Recrutement
- Community Health Network (The University of Texas MD Anderson Cancer Center)
-
Chercheur principal:
- Funda Meric-Bernstam, MD
-
Contact:
- Kshipra Sharma, MPH, MS
- Numéro de téléphone: 713-745-8431
- E-mail: Ksharma2@MDAnderson.org
-
-
Maine
-
Augusta, Maine, États-Unis, 04330
- Recrutement
- Harold Alfond Center for Cancer Care
-
Contact:
- Sandra Neptune, BSN, RN
- Numéro de téléphone: 207-626-4811
- E-mail: sandra.neptune@mainegeneral.org
-
Chercheur principal:
- Lindsay Hathaway, MD
-
Augusta, Maine, États-Unis, 04330
- Recrutement
- Jackson Laboratory - Maine Cancer Genomics Initiative
-
Contact:
- Petra Helbig, CCRP
- Numéro de téléphone: 207-664-4659
- E-mail: Petra.Helbig@jax.org
-
Chercheur principal:
- Jens Rueter, MD
-
Belfast, Maine, États-Unis, 04915
- Recrutement
- Waldo County General Hospital
-
Chercheur principal:
- Roger Inhorn, MD
-
Contact:
- Jen - Dalton, MHA, BSN, RN
- Numéro de téléphone: 2072948291
- E-mail: JDalton@mmc.org
-
Biddeford, Maine, États-Unis, 04005
- Recrutement
- SMHC Cancer Care and Blood Disorders -Biddeford
-
Chercheur principal:
- Roger Inhorn, MD
-
Contact:
- Jen - Dalton
- Numéro de téléphone: 2072948291
- E-mail: JDalton@mmc.org
-
Brewer, Maine, États-Unis, 04412
- Recrutement
- Northern Light Cancer Care
-
Chercheur principal:
- Sarah Sinclair, MD
-
Contact:
- Carla Mancini, MHA, BSN, RN
- Numéro de téléphone: 207-973-5581
- E-mail: cmancini@northernlight.org
-
Brewer, Maine, États-Unis, 04412
- Recrutement
- Raish Peavey Haskell Children's Cancer and Treatment Center
-
Chercheur principal:
- Sarah Sinclair, MD
-
Contact:
- Carla C Mancini, RN, BSN, OCN
- Numéro de téléphone: 2079735581
- E-mail: cmancini@northernlight.org
-
Brunswick, Maine, États-Unis, 04011
- Recrutement
- MaineHealth Cancer Care -Brunswick
-
Chercheur principal:
- Roger Inhorn, MD
-
Contact:
- Jen - Dalton, MHA, BSN, RN
- Numéro de téléphone: 2072948291
- E-mail: JDalton@mmc.org
-
Kennebunk, Maine, États-Unis, 04043
- Recrutement
- New England Cancer Specialist
-
Chercheur principal:
- Christian Thomas, MD
-
Contact:
- Patricia C Collins
- Numéro de téléphone: 2073033422
- E-mail: collip@newecs.org
-
Kittery, Maine, États-Unis, 03904
- Recrutement
- York Hopsital Oncology & Infusion Care in Kittery
-
Chercheur principal:
- Marilyn McLaughlin, MD
-
Contact:
- Brenda i Kiberd, RN
- Numéro de téléphone: 2073616115
- E-mail: Brenda.Kiberd@yorkhospital.com
-
Norway, Maine, États-Unis, 04268
- Recrutement
- Stephens Memorial Hospital
-
Chercheur principal:
- Roger Inhorn, MD
-
Contact:
- Jen - Dalton, MHA, BSN, RN
- Numéro de téléphone: 2072948291
- E-mail: JDalton@mmc.org
-
Rockport, Maine, États-Unis, 04856
- Recrutement
- Penobscot Bay Medical Center
-
Chercheur principal:
- Roger Inhorn, MD
-
Contact:
- Jen - Dalton, MHA, BSN, RN
- Numéro de téléphone: 2072948291
- E-mail: JDalton@mmc.org
-
Sanford, Maine, États-Unis, 04073
- Recrutement
- SMHC Cancer Care and Blood Disorders -Sandford
-
Chercheur principal:
- Roger Inhorn, MD
-
Contact:
- Jen - Dalton, MHA, BSN, RN
- Numéro de téléphone: 2072948291
- E-mail: JDalton@mmc.org
-
Scarborough, Maine, États-Unis, 04074
- Recrutement
- Maine Children's Cancer Program
-
Chercheur principal:
- Roger Inhorn, MD
-
Contact:
- Jen - Dalton, MHA, BSN, RN
- Numéro de téléphone: 2072948291
- E-mail: JDalton@mmc.org
-
Scarborough, Maine, États-Unis, 04074
- Recrutement
- Maine Medical Partner's Women's Health
-
Chercheur principal:
- Roger Inhorn, MD
-
Contact:
- Jen - Dalton, MHA, BSN, RN
- Numéro de téléphone: 2072948291
- E-mail: JDalton@mmc.org
-
Scarborough, Maine, États-Unis, 04074
- Recrutement
- New England Cancer Specialist
-
Chercheur principal:
- Christian Thomas, MD
-
Contact:
- Patricia Collins, BA, CCRC
- Numéro de téléphone: 207-303-3422
- E-mail: collip@newecs.org
-
South Portland, Maine, États-Unis, 04106
- Recrutement
- MaineHealth Cancer Care -South Portland
-
Contact:
- Jen Dalton, MHA, BSN, RN
- Numéro de téléphone: 207-294-8291
- E-mail: JDalton@mmc.org
-
Chercheur principal:
- Roger Inhorn, MD
-
Topsham, Maine, États-Unis, 04086
- Recrutement
- New England Cancer Specialist
-
Chercheur principal:
- Christian Thomas, MD
-
Contact:
- Patricia C Collins, BA, CCRC
- Numéro de téléphone: 12073033422
- E-mail: collip@newecs.org
-
Wells, Maine, États-Unis, 04090
- Recrutement
- York Hospital Oncology & Infusion Care in Wells
-
Chercheur principal:
- Marilyn McLaughlin, MD
-
Contact:
- Brenda Kiberd, RN
- Numéro de téléphone: 207-361-6115
- E-mail: Brenda.Kiberd@yorkhospital.com
-
York Village, Maine, États-Unis, 03909
- Recrutement
- York Hospital Oncology & Infusion Care in York
-
Chercheur principal:
- Marilyn McLaughlin, MD
-
Contact:
- Brenda i Kiberd, RN
- Numéro de téléphone: 2073616115
- E-mail: Brenda.Kiberd@yorkhospital.com
-
-
Michigan
-
Ann Arbor, Michigan, États-Unis, 48109
- Actif, ne recrute pas
- University of Michigan
-
Ann Arbor, Michigan, États-Unis, 48106
- Recrutement
- Trinity Health Ann Arbor Hospital
-
Chercheur principal:
- Elie Dib, MD
-
Contact:
- Numéro de téléphone: 7347123671
- E-mail: MCRCwebsitecontactform@trinity-health.org
-
Detroit, Michigan, États-Unis, 48236
- Recrutement
- Henry Ford Health Saint John Hospital
-
Chercheur principal:
- Carrie Dul, MD
-
Contact:
- Numéro de téléphone: 7347123671
- E-mail: MCRCwebsitecontactform@trinity-health.org
-
Flint, Michigan, États-Unis, 48503
- Recrutement
- Genesys Hurley Cancer Institute
-
Chercheur principal:
- Paul Adams, MD
-
Contact:
- Numéro de téléphone: 7347123671
- E-mail: MCRCwebsitecontactform@trinity-health.org
-
Grand Rapids, Michigan, États-Unis, 49503
- Recrutement
- Cancer Research Consortium of West Michigan
-
Contact:
- Connie Szczepanek, RN
- Numéro de téléphone: 616-391-1230
- E-mail: crcwm-regulatory@crcwm.org
-
Chercheur principal:
- Kathleen J. Yost, MD
-
Lansing, Michigan, États-Unis, 48912
- Recrutement
- University of Michigan Health - Sparrow Lansing
-
Chercheur principal:
- Gordan Srkalovic, MD
-
Contact:
- Numéro de téléphone: 7347123671
- E-mail: MCRCwebsitecontactform@trinity-health.org
-
Livonia, Michigan, États-Unis, 48154
- Recrutement
- Trinity Health Livonia Hospital
-
Chercheur principal:
- Amit Mohindra, MD
-
Contact:
- Numéro de téléphone: 7347127251
- E-mail: MCRCwebsitecontactform@trinity-health.org
-
Pontiac, Michigan, États-Unis, 48341
- Recrutement
- Trinity Health Oakland Hospital
-
Chercheur principal:
- Julie Goodman, MD
-
Contact:
- Numéro de téléphone: 7347123671
- E-mail: MCRCwebsitecontactform@trinity-health.org
-
Saginaw, Michigan, États-Unis, 48601
- Recrutement
- MyMichigan Medical Center Saginaw
-
Chercheur principal:
- Nicholas Damico, MD
-
Contact:
- Numéro de téléphone: 7347123671
- E-mail: MCRCwebsitecontactform@trinity-health.org
-
Traverse City, Michigan, États-Unis, 48341
- Recrutement
- Michigan Cancer Research Consortium
-
Chercheur principal:
- Philip Stella, MD
-
Contact:
- Beth LaVasseur, RN, MS
- Numéro de téléphone: 734-712-7251
- E-mail: Beth.LaVasseur@stjoeshealth.org
-
Contact:
- Numéro de téléphone: 877-590-5995
-
Warren, Michigan, États-Unis, 48093
- Recrutement
- Henry Ford Health Warren Hospital
-
Chercheur principal:
- Carrie Dul, MD
-
Contact:
- Numéro de téléphone: 7347123671
- E-mail: MCRCwebsitecontactform@trinity-health.org
-
-
Nebraska
-
Omaha, Nebraska, États-Unis, 68198
- Recrutement
- University of Nebraska Medical Center
-
Chercheur principal:
- Alissa Marr, MD
-
Contact:
- Micki Bethea, BS
- Numéro de téléphone: 402-559-8011
- E-mail: mbethea@unmc.edu
-
-
New Hampshire
-
Concord, New Hampshire, États-Unis, 03103
- Recrutement
- NH Oncology - Hematology, PA
-
Contact:
- Ali Fleury
- Numéro de téléphone: 6033146888
- E-mail: A.Fleury@nhoh.com
-
Chercheur principal:
- Michael Buff, MD
-
Manchester, New Hampshire, États-Unis, 03103
- Recrutement
- Solinsky Center for Cancer Care
-
Contact:
- Ali Fleury, BA, CCRP
- Numéro de téléphone: 603-314-6888
- E-mail: A.Fleury@nhoh.com
-
Chercheur principal:
- Michael Buff, MD
-
Portsmouth, New Hampshire, États-Unis, 03801
- Recrutement
- New England Cancer Specialist
-
Chercheur principal:
- Christian Thomas, MD
-
Contact:
- Patricia C Collins, BA, CCRC
- Numéro de téléphone: 2073033422
- E-mail: collip@newecs.org
-
-
New Mexico
-
Albuquerque, New Mexico, États-Unis, 87110
- Recrutement
- Presbyterian Kaseman Hospital
-
Chercheur principal:
- Bernard Tawfik, MD
-
Contact:
- Monique Robertson, RN
- Numéro de téléphone: (505)- 559-6100
- E-mail: mrobertso2@phs.org
-
Albuquerque, New Mexico, États-Unis, 87102
- Recrutement
- Lovelace Medical Center - Saint Joseph Square
-
Chercheur principal:
- Bernard Tawfik, MD
-
Contact:
- Leslie Byatt
- Numéro de téléphone: (505) -925-0366
- E-mail: lpbyatt@salud.unm.edu
-
Albuquerque, New Mexico, États-Unis, 87131
- Recrutement
- The University of New Mexico Comprehensive Cancer Center
-
Chercheur principal:
- Bernard Tawfik, MD
-
Contact:
- Sheri Westgate, RN-BSN, OCN
- Numéro de téléphone: (505) -925-0383
- E-mail: swestgate@salud.unm.edu
-
Las Cruces, New Mexico, États-Unis, 88011
- Recrutement
- Memorial Medical Center
-
Chercheur principal:
- Bernard Tawfik, MD
-
Contact:
- Kim Hoffman, RN
- Numéro de téléphone: (575)- 556-6545
- E-mail: kim.hoffman@lpnt.net
-
Rio Rancho, New Mexico, États-Unis, 87124
- Recrutement
- Presbyterian Rust Medical Center
-
Chercheur principal:
- Bernard Tawfik, MD
-
Contact:
- Andrea Yost
- Numéro de téléphone: (505) -253-7878
- E-mail: ayost3@phs.org
-
-
New York
-
Lake Success, New York, États-Unis, 11042
- Recrutement
- Northwell Health Monter Cancer Center
-
Contact:
- Mary Agnes Templeton
- Numéro de téléphone: 516-734-8979
- E-mail: mtempleton@northwell.edu
-
Chercheur principal:
- Marina Frimer, MD
-
Mount Kisco, New York, États-Unis, 10549
- Recrutement
- Northern Westchester Hospital
-
Chercheur principal:
- Marina Frimer, MD
-
Contact:
- Jemima Jacob, MPH
- Numéro de téléphone: 914-666-1366
- E-mail: jjacob22@northwell.edu
-
New Hyde Park, New York, États-Unis, 11040
- Recrutement
- Cohen Children's Medical Center
-
Contact:
- Shreya Seepersaud
- Numéro de téléphone: 718-470-7146
- E-mail: sseepersaud2@northwell.edu
-
Chercheur principal:
- Marina Frimer, MD
-
New York, New York, États-Unis, 10065
- Recrutement
- Manhattan Eye, Ear, and Throat Hospital
-
Chercheur principal:
- Marina Frimer, MD
-
Contact:
- Leila Nasr
- E-mail: lnasr@northwell.edu
-
New York, New York, États-Unis, 10305
- Recrutement
- Staten Island University Hospital
-
Chercheur principal:
- Marina Frimer, MD
-
Contact:
- Sammi Ruan
- Numéro de téléphone: 718-226-1489
- E-mail: sruan2@northwell.edu
-
Contact:
- Melissa McCarthy
- Numéro de téléphone: 718-226-1805
- E-mail: mccarthy22@northwell.edu
-
Rego Park, New York, États-Unis, 11374
- Recrutement
- Queens Cancer Center
-
Chercheur principal:
- Marina Frimer, MD
-
Contact:
- Harmandeep Kaur
- Numéro de téléphone: 718-412-0773
- E-mail: hkaur37@northwell.edu
-
Sleepy Hollow, New York, États-Unis, 10591
- Recrutement
- Phelps Hospital
-
Chercheur principal:
- Marina Frimer, MD
-
Contact:
- Barbara Turner, RN
- Numéro de téléphone: 914-269-1949
- E-mail: Bturner1@northwell.edu
-
Contact:
- Shyrley Gomez
- E-mail: Sgomez21@northwell.edu
-
-
North Carolina
-
Chapel Hill, North Carolina, États-Unis, 27599
- Recrutement
- Lineberger Comprehensive Cancer Center
-
Chercheur principal:
- Shetal Patel, MD
-
Contact:
- Emmie Cole
- Numéro de téléphone: 919-966-4432
- E-mail: emmie_cole@med.unc.edu
-
Charlotte, North Carolina, États-Unis, 28277
- Recrutement
- Atrium Health's Levine Cancer Institute
-
Chercheur principal:
- Kathryn F. Mileham, MD, FACP
-
Contact:
- Jenna Gregory, MS, RN
- E-mail: Jenna.Gregory@atriumhealth.org
-
-
North Dakota
-
Bismarck, North Dakota, États-Unis, 58501
- Recrutement
- Sanford Health- Bismarck
-
Contact:
- Peter Kurniali, MD
- Numéro de téléphone: 701-323-5741
- E-mail: peter.kurniali@sanfordhealth.org
-
Chercheur principal:
- Peter Kurniali, MD
-
Fargo, North Dakota, États-Unis, 58122
- Recrutement
- Sanford Health- Fargo
-
Contact:
- Anu Gaba, MD
- Numéro de téléphone: 701-234-6161
- E-mail: anu.gaba@sanfordhealth.org
-
Chercheur principal:
- Anu Gaba, MD
-
-
Ohio
-
Cincinnati, Ohio, États-Unis, 45219
- Recrutement
- University of Cincinnati Medical Center
-
Chercheur principal:
- Davendra Sohal, MD
-
Contact:
- Kayla Webb, MSN, RN
- Numéro de téléphone: 513-584-0599
- E-mail: webb2ka@ucmail.uc.edu
-
Kettering, Ohio, États-Unis, 45429
- Recrutement
- Kettering Health
-
Contact:
- Allison Dymacek, BSN, RN
- Numéro de téléphone: 937-395-8367
- E-mail: allison.dymacek@ketteringhealth.org
-
Chercheur principal:
- Lex Leonhardt, DO
-
West Chester, Ohio, États-Unis, 45069
- Recrutement
- West Chester Hospital
-
Chercheur principal:
- Trisha Wise-Draper, MD
-
Contact:
- Kayla Webb, MSN, RN
- Numéro de téléphone: 513-584-0599
- E-mail: webb2ka@ucmail.uc.edu
-
-
Oregon
-
Portland, Oregon, États-Unis, 97213
- Recrutement
- Providence Health & Services
-
Chercheur principal:
- Evthokia Hobbs, MD
-
Contact:
- Isa Ngirailemesang
- Numéro de téléphone: 971-358-2056
- E-mail: Isa.Ngirailemesang@providence.org
-
-
Pennsylvania
-
Allentown, Pennsylvania, États-Unis, 18103
- Recrutement
- Lehigh Valley Hospital - Cedar Crest
-
Contact:
- Numéro de téléphone: 734-712-3671
- E-mail: MCRCwebsitecontactform@trinity-health.org
-
Chercheur principal:
- Maged Khalil, MD
-
Bethlehem, Pennsylvania, États-Unis, 18017
- Recrutement
- Lehigh Valley Hospital- Muhlenberg
-
Chercheur principal:
- Maged Khalil, MD
-
Contact:
- Numéro de téléphone: 7347127251
- E-mail: MCRCwebsitecontactform@trinity-health.org
-
East Stroudsburg, Pennsylvania, États-Unis, 18301
- Recrutement
- Pocono Medical Center
-
Chercheur principal:
- Maged Khalil, MD
-
Contact:
- Numéro de téléphone: 7347127251
- E-mail: MCRCwebsitecontactform@trinity-health.org
-
Hazleton, Pennsylvania, États-Unis, 18201
- Recrutement
- Lehigh Valley Hospital-Hazleton
-
Chercheur principal:
- Maged Khalil, MD
-
Contact:
- Numéro de téléphone: 7347127251
- E-mail: MCRCwebsitecontactform@trinity-health.org
-
Philadelphia, Pennsylvania, États-Unis, 19111
- Recrutement
- Fox Chase Cancer Center
-
Chercheur principal:
- Margaret von Mehren, MD
-
Contact:
- Fathima S Sheriff
- Numéro de téléphone: 215-728-4094
- E-mail: fathima.sheriff@fccc.edu
-
-
South Carolina
-
Bluffton, South Carolina, États-Unis, 29910
- Recrutement
- SC Cancer Specialists at St. Joseph's/Candler Bluffton
-
Chercheur principal:
- Mark Taylor, MD
-
Contact:
- Stephanie Smith, RN, MSN, OCN
- Numéro de téléphone: 19128195723
- E-mail: smiths1@sjchs.org
-
Bluffton, South Carolina, États-Unis, 29910
- Recrutement
- St. Joseph's/Candler Smith
-
Chercheur principal:
- Mark Taylor, MD
-
Contact:
- Stephanie Smith, RN, MSN, OCN
- Numéro de téléphone: 19128195723
- E-mail: smiths1@sjchs.org
-
Bluffton, South Carolina, États-Unis, 29910
- Recrutement
- Summit Cancer Care at St. Josph's/Candler Bluffton
-
Chercheur principal:
- Mark Taylor, MD
-
Contact:
- Stephanie Smith, RN, MSN, OCN
- Numéro de téléphone: 19128195723
- E-mail: smiths1@sjchs.org
-
Hilton Head Island, South Carolina, États-Unis, 29926
- Recrutement
- South Carolina Cancer Specialists
-
Chercheur principal:
- Mark Taylor, MD
-
Contact:
- Stephanie Smith, RN, MSN, OCN
- Numéro de téléphone: 19128195723
- E-mail: smiths1@sjchs.org
-
-
South Dakota
-
Sioux Falls, South Dakota, États-Unis, 57104
- Recrutement
- Sanford Cancer Center Oncology Clinic and Pharmacy
-
Chercheur principal:
- Steven Powell, MD
-
Contact:
- Steven Powell, MD
- Numéro de téléphone: 605-328-8000
- E-mail: steven.powell@sanfordhealth.org
-
-
Tennessee
-
Nashville, Tennessee, États-Unis, 37203
- Recrutement
- Tennessee Oncology - Nashville / Sarah Cannon Research Institute
-
Contact:
- Ethan Trull
- Numéro de téléphone: 615-329-7274
- E-mail: Ethan.Trull@SarahCannon.com
-
Chercheur principal:
- Meredith McKean, MD, MPH
-
-
Texas
-
Houston, Texas, États-Unis, 77030
- Recrutement
- The University of Texas MD Anderson Cancer Center
-
Chercheur principal:
- Funda Meric-Bernstam, MD
-
Contact:
- Kshipra Sharma, MPH, MS
- Numéro de téléphone: 713-745-8431
- E-mail: Ksharma2@MDAnderson.org
-
-
Utah
-
Cedar City, Utah, États-Unis, 84720
- Recrutement
- Cedar City Hospital, SW Cancer Clinic, Sandra Maxwell Cancer Center
-
Chercheur principal:
- Ramya Thota, MD
-
Contact:
- Jake Kolu
- Numéro de téléphone: 435-705-1632
- E-mail: Jake.Kolu@imail.org
-
Chercheur principal:
- Derrick Haslem, MD
-
Salt Lake City, Utah, États-Unis, 84107
- Recrutement
- Intermountain Healthcare
-
Contact:
- Tracy Taylor
- Numéro de téléphone: 801-507-3953
- E-mail: tracy.taylor@imail.org
-
Chercheur principal:
- Ramya Thota, M.D.
-
Chercheur principal:
- Derrick Haslem, M.D.
-
St. George, Utah, États-Unis, 84770
- Recrutement
- Dixie Regional Medical Center-River Road Campus
-
Chercheur principal:
- Ramya Thota, MD
-
Contact:
- Jake Kolu
- Numéro de téléphone: 435-705-1632
- E-mail: Jake.Kolu@imail.org
-
Chercheur principal:
- Derrick Haslem, MD
-
-
Virginia
-
Fairfax, Virginia, États-Unis, 22042
- Recrutement
- Inova Schar Cancer Institute
-
Chercheur principal:
- Timothy Cannon, MD
-
Contact:
- Roxana Comfort, CRC
- Numéro de téléphone: 571-472-0628
- E-mail: roxana.comfort@inova.org
-
-
Washington
-
Bonney Lake, Washington, États-Unis, 98391
- Recrutement
- Northwest Medical Specialties
-
Contact:
- Jennifer Spokely
- Numéro de téléphone: 253-999-3701
- E-mail: research@southsoundcare.org
-
Chercheur principal:
- Frank Senecal, MD
-
Federal Way, Washington, États-Unis, 98003
- Recrutement
- Northwest Medical Specialties
-
Contact:
- Jennifer Spokely
- Numéro de téléphone: 253-999-3701
- E-mail: research@southsoundcare.org
-
Chercheur principal:
- Frank Senecal, MD
-
Gig Harbor, Washington, États-Unis, 98332
- Recrutement
- Northwest Medical Specialties
-
Contact:
- Jennifer Spokely
- Numéro de téléphone: 253-999-3701
- E-mail: research@southsoundcare.org
-
Chercheur principal:
- Frank Senecal, MD
-
Olympia, Washington, États-Unis, 98502
- Recrutement
- Northwest Medical Specialties
-
Contact:
- Jennifer Spokely
- Numéro de téléphone: 253-999-3701
- E-mail: research@southsoundcare.org
-
Chercheur principal:
- Frank Senecal, MD
-
Puyallup, Washington, États-Unis, 98373
- Recrutement
- Northwest Medical Specialties
-
Chercheur principal:
- Frank Senecal, MD
-
Contact:
- Jennifer Spokely
- Numéro de téléphone: 253-999-3701
- E-mail: reserch@southsoundcare.org
-
Seattle, Washington, États-Unis, 98104
- Recrutement
- Swedish Cancer Institute
-
Chercheur principal:
- Philip Gold, MD
-
Contact:
- Sidney Ching
- Numéro de téléphone: 206-386-3142
- E-mail: sidney.ching@swedish.org
-
Tacoma, Washington, États-Unis, 98405
- Recrutement
- Northwest Medical Specialties
-
Chercheur principal:
- Frank Senecal, MD
-
Contact:
- Jennifer Spokely
- Numéro de téléphone: 253-999-3701
- E-mail: reserch@southsoundcare.org
-
-
Wisconsin
-
Burlington, Wisconsin, États-Unis, 53105
- Recrutement
- Aurora Cancer Care - Burlington
-
Chercheur principal:
- Antony Ruggeri, MD
-
Contact:
- Michelle Toutloff, RN, CCRP
- Numéro de téléphone: 9204567880
- E-mail: Michelle.Martin2@aah.org
-
Germantown, Wisconsin, États-Unis, 53022
- Recrutement
- Aurora Health Care - Germantown Health Center
-
Chercheur principal:
- Antony Ruggeri, MD
-
Contact:
- Michelle Toutloff, RN, CCRP
- Numéro de téléphone: 9204567880
- E-mail: Michelle.Martin2@aah.org
-
Grafton, Wisconsin, États-Unis, 53024
- Recrutement
- Aurora Cancer Care - Grafton
-
Chercheur principal:
- Antony Ruggeri, MD
-
Contact:
- Michelle Toutloff, RN, CCRP
- Numéro de téléphone: 9204567880
- E-mail: Michelle.Martin2@aah.org
-
Green Bay, Wisconsin, États-Unis, 54311
- Recrutement
- Aurora BayCare Medical Center
-
Chercheur principal:
- Antony Ruggeri, MD
-
Contact:
- Michelle Toutloff, RN, CCRP
- Numéro de téléphone: 9204567880
- E-mail: Michelle.Martin2@aah.org
-
Kenosha, Wisconsin, États-Unis, 53142
- Recrutement
- Aurora Cancer Care - Kenosha South
-
Chercheur principal:
- Antony Ruggeri, MD
-
Contact:
- Michelle Toutloff, RN, CCRP
- Numéro de téléphone: 9204567880
- E-mail: Michelle.Martin2@aah.org
-
Marinette, Wisconsin, États-Unis, 54143
- Recrutement
- Aurora Bay Area Medical Center
-
Chercheur principal:
- Antony Ruggeri, MD
-
Contact:
- Michelle Toutloff, RN, CCRP
- Numéro de téléphone: 9204567880
- E-mail: Michelle.Martin2@aah.org
-
Milwaukee, Wisconsin, États-Unis, 53215
- Recrutement
- Aurora St. Luke's Medical Center
-
Chercheur principal:
- Antony Ruggeri, MD
-
Contact:
- Michelle M Toutloff, RN, CCRP
- Numéro de téléphone: 9204567880
- E-mail: Michelle.Martin2@aah.org
-
Milwaukee, Wisconsin, États-Unis, 53209
- Recrutement
- Aurora Cancer Care Milwaukee
-
Chercheur principal:
- Antony Ruggeri, MD
-
Contact:
- Michelle M Toutloff, RN, CCRP
- Numéro de téléphone: 9204567880
- E-mail: Michelle.Martin2@aah.org
-
Milwaukee, Wisconsin, États-Unis, 53223
- Recrutement
- Aurora Sinai Medical Center
-
Chercheur principal:
- Antony Ruggeri, MD
-
Contact:
- Michelle Toutloff, RN, CCRP
- Numéro de téléphone: 9204567880
- E-mail: Michelle.Martin2@aah.org
-
Milwaukee, Wisconsin, États-Unis, 53227
- Recrutement
- Aurora West Allis Medical Center
-
Chercheur principal:
- Antony Ruggeri, MD
-
Contact:
- Michelle Toutloff, RN, CCRP
- Numéro de téléphone: 9204567880
- E-mail: Michelle.Martin2@aah.org
-
Oshkosh, Wisconsin, États-Unis, 54904
- Recrutement
- Vince Lombardi Cancer Clinic - Oshkosh
-
Chercheur principal:
- Antony Ruggeri, MD
-
Contact:
- Michelle Toutloff, RN, CCRP
- Numéro de téléphone: 9204567880
- E-mail: Michelle.Martin2@aah.org
-
Racine, Wisconsin, États-Unis, 53406
- Recrutement
- Aurora Cancer Care - Racine
-
Chercheur principal:
- Antony Ruggeri, MD
-
Contact:
- Michelle Toutloff, RN, CCRP
- Numéro de téléphone: 9204567880
- E-mail: Michelle.Martin2@aah.org
-
Sheboygan, Wisconsin, États-Unis, 53081
- Recrutement
- Vince Lombardi Cancer Center
-
Chercheur principal:
- Antony Ruggeri, MD
-
Contact:
- Michelle Toutloff, RN, CCRP
- Numéro de téléphone: 9204567880
- E-mail: Michelle.Martin2@aah.org
-
Summit, Wisconsin, États-Unis, 53066
- Recrutement
- Aurora Medical Center in Summit
-
Chercheur principal:
- Antony Ruggeri, MD
-
Contact:
- Michelle Toutloff, RN, CCRP
- Numéro de téléphone: 9204567880
- E-mail: Michelle.Martin2@aah.org
-
Two Rivers, Wisconsin, États-Unis, 54241
- Recrutement
- Vince Lombardi Cancer Clinic - Two Rivers
-
Chercheur principal:
- Antony Ruggeri, MD
-
Contact:
- Michelle Toutloff, RN, CCRP
- Numéro de téléphone: 9204567880
- E-mail: Michelle.Martin2@aah.org
-
Wauwatosa, Wisconsin, États-Unis, 53226
- Recrutement
- Aurora Cancer Care - Milwaukee West
-
Chercheur principal:
- Antony Ruggeri, MD
-
Contact:
- Michelle Toutloff, RN, CCRP
- Numéro de téléphone: 920-456-7880
- E-mail: Michelle.Martin2@aah.org
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
-
12 years of age or older (*Restrictions apply. Not all therapies are available for patients <18)
-
Histologically-proven locally advanced or metastatic solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma who is no longer benefiting from standard anti-cancer treatment or for whom, in the opinion of the treating physician, no such treatment is available or indicated (except under the circumstance in which the TAPUR arm is designed to provide additional evidence to support an existing FDA indication).
-
Performance status 0-2 (Per Eastern Cooperative Oncology Group (ECOG) criteria)
-
Patients must have acceptable organ function as defined below. However, as noted above, drug-specific inclusion/exclusion criteria specified in the protocol appendix for each agent will take precedence for this and all inclusion criteria:
- Absolute neutrophil count ≥ 1500 µl
- Hemoglobin ≥ 9.0 g/dl
- Platelets ≥ 75,000/µl
- Total bilirubin < 2.0 mg/ dl, except in patients with Gilbert's Syndrome
- Aspartate aminotransferase (AST) serum glutamic-oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT) serum glutamic-pyruvic transaminase (SGPT) < 2.5 x institutional upper limit of normal (ULN) (or < 5 x ULN in patients with known hepatic metastases)
- Serum creatinine ≤ 1.5 × ULN or calculated or measured creatinine clearance ≥ 50 mL/min/1.73 m2
-
Patients must have disease that can be objectively measured by physical, laboratory or radiographic exam (per RECIST v1.1 for solid tumor, Lugano criteria for non-Hodgkin lymphoma or International Myeloma Working Group criteria for multiple myeloma).
-
Results must be available from a genomic test or immunohistochemistry (IHC) test for protein expression performed in a Clinical Laboratory Improvement Amendments (CLIA)-certified and College of American Pathologists (CAP)-accredited or New York State accredited (for labs offering services to residents of NY) laboratory. Labs that have registered the test with the NIH Genetic Testing Registry or that provide a report that has been designated as optimized for TAPUR participation are preferred, but not required. The genomic or IHC test used to qualify a patient for participation in TAPUR may have been performed on any specimen of the patient's tumor obtained at any point during the patient's care at the discretion of the patient's treating physician. Genomic assays performed on cell-free DNA in plasma ("liquid biopsies") will also be acceptable if the genomic analysis is performed in a laboratory that meets the criteria described above.
-
Ability to understand and the willingness to sign a written informed consent/assent document.
-
Have a tumor genomic profile for which single agent treatment with one of the FDA approved targeted anti-cancer drugs included in this study has potential clinical benefit based on the criteria described in protocol.
-
For orally administered drugs, the patient must be able to swallow and tolerate oral medication and must have no known malabsorption syndrome.
-
Because of the risks of drug treatment to the developing fetus, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study participation, and for four months following completion of study therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study or if she is the partner of a male participant in this study and becomes pregnant while he is participating in this study, she should inform her or her partner's treating physician immediately as well as her obstetrician. Female study patients who become pregnant must immediately discontinue treatment with any study therapy. Male patients should avoid impregnating a female partner. Male study patients, even if surgically sterilized, (i.e. post-vasectomy) must agree to one of the following: practice effective barrier contraception during the entire study treatment period and for a specified amount of time the last dose of study treatment, or completely abstain from sexual intercourse.
Note: TAPUR does not explicitly exclude any type of solid tumor, but the patient must have measurable and evaluable disease per RECIST v1.1.
Exclusion Criteria:
- Patients whose disease is not measurable or cannot be assessed by radiographic imaging or physical examination (e.g., elevated serum tumor marker only) are not eligible
- Patients with primary brain tumors or new, untreated or progressive leptomeningeal metastases are excluded
- Patients with previously treated brain metastases or previously treated leptomeningeal disease are eligible, provided that the patient has not experienced a seizure or had a clinically significant change in neurological status within the 1 months prior to registration. All patients with previously treated brain metastases must be clinically stable for at least 1 month after completion of treatment and off steroid treatment for one month prior to study enrollment.
- Patients with known progressive brain metastases are eligible but additional eligibility criteria apply.
Note: there are additional exclusion criteria that may apply
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Non randomisé
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Autre: Group 5 (CSF1R,PDGFR,VEGFR)
Participants receive sunitinib - dosage, frequency and duration per label; acceptable genomic matches include CSF1R, PDGFR, VEGFR1/2/3, KIT, FLT-3, RET, FGFR1/2/3, VHL amplifications or mutations |
drug
Autres noms:
|
|
Autre: Group 8 (ERBB2)
Participants receive trastuzumab and pertuzumab - dosage, frequency and duration per label; acceptable genomic matches include ERBB2 amplification or overexpression, and specific ERBB2 mutations |
drug
Autres noms:
|
|
Autre: Group 9 (BRAF V600E/D/K/R)
Participants receive vemurafenib and cobimetinib - dosage, frequency and duration per label; acceptable genomic matches include BRAF V600E/D/K/R mutations |
drug
Autres noms:
|
|
Autre: Group 14 (BRCA1/2; ATM)
Participants receive olaparib - dosage, frequency and duration per label; acceptable genomic matches include germline or somatic BRCA1/2 inactivating mutations; ATM mutations or deletions |
drug
Autres noms:
|
|
Autre: Group 16 (MSI-H, high mutational load and others)
Participants receive nivolumab and ipilimumab - dosage, frequency and duration per label; acceptable genomic matches include MSI high status, high tumor mutational burden, MLH1, MSH2/6, PMS2, EPCAM mutations, specific POLE or POLD1 mutations, BRCA1/2, ATM, MSH3, PMS1, MLH3, EXO1, RFC1/2/3/4/5, PCNA, RPA1/2/3/4, and SSBP1 loss of function mutations |
drug
Autres noms:
|
|
Autre: Group 17 (CDKN2A, CDK4, CDK6)
Participants receive abemaciclib - dosage, frequency and duration per label; acceptable genomic matches include CDKN2A loss or mutation, CDK4, CDK6 amplifications, CDKN2B loss or mutation |
drug
Autres noms:
|
|
Autre: Group 19 (BRCA1/2, PALB2)
Participants receive talazoparib - dosage, frequency and duration per label; acceptable genomic matches include germline or somatic BRCA1/2 and PALB2 mutations |
drug
Autres noms:
|
|
Autre: Group 21 (BRCA1/2, PALB2, ATM, and others)
Participants receive atezolizumab plus talazoparib - dosage, frequency and duration per label; acceptable genomic matches include germline or somatic mutations in BRCA1/2, PALB2, ATM, ATR, CHEK2, FANCA, RAD51C, NBN, MLH1, MRE11A, CDK12; positive genomic instability score reported on the Myriad MyChoice CDx test; or Genomic Loss of Heterozygosity (LOH) Score above threshold as reported on a FoundationOne CDx test or another qualifying test for TAPUR with MTB approval |
drug
Autres noms:
|
|
Autre: Group 24 (ERBB2)
Participants receive tucatinib plus trastuzumab SC - dosage, frequency and duration per label; acceptable genomic matches include ERBB2 amplification or overexpression, and specific ERBB2 mutations |
drug
Autres noms:
|
|
Autre: Group 25
Participants receive futibatinib- dosage, frequency and duration per label; acceptable genomic matches include FGFR 1,2,3,4 fusion (or other rearrangement) or mutation |
drug
Autres noms:
|
|
Autre: Group 26 (BRAF V600 E mutation )
Participants receive Dabrafenib plus Trametinib - dosage, frequency and duration per label; acceptable genomic matches include BRAF V600 E mutation . |
Drug
Autres noms:
|
|
Autre: Group 27 (ERBB2 amplification, ERBB2 (HER2) IHC2+ or IHC3+ overexpression)
Participants receive Fam-trastuzumab deruxtecan-nxki (ENHERTU®) - dosage, frequency and duration per label; acceptable genomic matches include ERBB2 amplification, For NSCLC Only-ERBB2 (HER2) IHC2+ or IHC3+ overexpression without ERBB2 amplification) |
Drug
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Objective Response Rate defined as % of participants in a cohort with complete or partial response or with stable disease according to standard response criteria
Délai: Assessed at 16 weeks of treatment
|
Each cohort includes participants with the same tumor type, genomic variant and study drug. For solid tumors, the Response Evaluation Criteria for Solid Tumors (RECIST) criteria will be used, for non-Hodgkin Lymphoma, the Lugano Criteria will be used, and for multiple myeloma, the International Uniform Response Criteria for Multiple Myeloma will be used. |
Assessed at 16 weeks of treatment
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Overall survival (OS)
Délai: Duration of survival from registration on study until death from any cause, assessed throughout end of study, up to 3 years
|
OS will be estimated using the Kaplan-Meier method |
Duration of survival from registration on study until death from any cause, assessed throughout end of study, up to 3 years
|
Collaborateurs et enquêteurs
Publications et liens utiles
Publications générales
- Alva AS, Mangat PK, Garrett-Mayer E, Halabi S, Hansra D, Calfa CJ, Khalil MF, Ahn ER, Cannon TL, Crilley P, Fisher JG, Haslem DS, Shrestha S, Antonelli KR, Butler NL, Warren SL, Rygiel AL, Ranasinghe S, Bruinooge SS, Schilsky RL. Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. J Clin Oncol. 2021 Aug 1;39(22):2443-2451. doi: 10.1200/JCO.20.02923. Epub 2021 Apr 12.
- Fisher JG, Tait D, Garrett-Mayer E, Halabi S, Mangat PK, Schink JC, Alvarez RH, Veljovich D, Cannon TL, Crilley PA, Pollock T, Calfa CJ, Al Baghdadi T, Thota R, Fleming N, Cotta JA, Rygiel AL, Warren SL, Schilsky RL. Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Target Oncol. 2020 Dec;15(6):733-741. doi: 10.1007/s11523-020-00753-7.
- Al Baghdadi T, Garrett-Mayer E, Halabi S, Mangat PK, Rich P, Ahn ER, Chai S, Rygiel AL, Osayameh O, Antonelli KR, Islam S, Bruinooge SS, Schilsky RL. Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Target Oncol. 2020 Dec;15(6):743-750. doi: 10.1007/s11523-020-00752-8.
- Gupta R, Meric-Bernstam F, Rothe M, Garrett-Mayer E, Mangat PK, D'Andre S, Ahn ER, O'Lone R, Halabi S, Grantham GN, Schilsky RL. Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With ERBB2 Amplification or ERBB2/3 Mutations: Results From the TAPUR Study. JCO Precis Oncol. 2022 Oct;6:e2200306. doi: 10.1200/PO.22.00306.
- Mangat PK, Kirkwood MK, Hinshaw DC, Garrett-Mayer E, Schilsky RL. Prevalence of targetable genomic alterations among a diverse population participating in the ASCO TAPUR Study. NPJ Precis Oncol. 2025 Jul 3;9(1):222. doi: 10.1038/s41698-025-00962-1.
- Worden FP, Pisick E, Rothe M, Mangat PK, Garrett-Mayer E, Khalil MF, Carrizosa DR, Bauman JR, Leidner RS, Duvivier HL, Fu S, Park MS, Yost KJ, Calfa CJ, Marr AS, Balmanoukian AS, Behl D, Cannon TL, Nabell L, Powell SF, Thota R, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Palbociclib in Patients With Head and Neck Cancer and Other Tumors With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2024 Oct;8:e2400477. doi: 10.1200/PO-24-00477. Epub 2024 Oct 16.
- Schuetze S, Rothe M, Mangat PK, Garrett-Mayer E, Meric-Bernstam F, Calfa CJ, Farrington LC, Livingston MB, Wentzel K, Behl D, Kier Y, Marr AS, von Mehren M, Press JZ, Thota R, Grantham GN, Gregory A, Hinshaw DC, Halabi S, Schilsky RL. Palbociclib in Patients With Soft Tissue Sarcoma With CDK4 Amplifications: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2024 Jul;8:e2400219. doi: 10.1200/PO.24.00219.
- Srkalovic G, Rothe M, Mangat PK, Garrett-Mayer E, Ahn ER, Brouse G, Chan J, Mehmi I, Khalil M, Duvivier HL, Gaba A, Leuva H, Thota R, Yost KJ, Grantham GN, Gregory A, Hinshaw DC, Halabi S, Schilsky RL. Talazoparib in Patients With Solid Tumors With BRCA1/2 Mutation: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2024 Jun;8:e2400026. doi: 10.1200/PO.24.00026.
- Cannon TL, Rothe M, Mangat PK, Garrett-Mayer E, Chiu VK, Hwang J, Vijayvergia N, Alese OB, Dib EG, Duvivier HL, Klute KA, Sahai V, Ahn ER, Bedano P, Behl D, Sinclair S, Thota R, Urba WJ, Yang ES, Grantham GN, Hinshaw DC, Gregory A, Halabi S, Schilsky RL. Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With ERBB2/3 Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. J Clin Oncol. 2024 Sep 20;42(27):3228-3237. doi: 10.1200/JCO.23.02078. Epub 2024 May 15.
- Perez JK, Kleber J, Rothe M, Mangat P, Garrett-Mayer E, Schilsky RL. Concordance in Molecular Tumor Board Case Reviews in the ASCO TAPUR Study. JCO Precis Oncol. 2024 Mar;8:e2300615. doi: 10.1200/PO.23.00615.
- Calfa CJ, Rothe M, Mangat PK, Garrett-Mayer E, Ahn ER, Burness ML, Gogineni K, Rohatgi N, Al Baghdadi T, Conlin A, Gaba A, Hamid O, Krishnamurthy J, Gavini NJ, Gold PJ, Rodon J, Rueter J, Thota R, Grantham GN, Hinshaw DC, Gregory A, Halabi S, Schilsky RL. Sunitinib in Patients With Breast Cancer With FGFR1 or FGFR2 Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2024 Feb;8:e2300513. doi: 10.1200/PO.23.00513.
- Meric-Bernstam F, Rothe M, Mangat PK, Garrett-Mayer E, Gutierrez R, Ahn ER, Cannon TL, Powell S, Krauss JC, Reynolds CM, von Mehren M, Behl D, Calfa CJ, Duvivier HL, Kaplan HG, Livingston MB, Sharma MR, Urba WJ, Grantham GN, Hinshaw DC, Gregory A, Halabi S, Schilsky RL. Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2023 Sep;7:e2300385. doi: 10.1200/PO.23.00385.
- Rohatgi N, Rothe M, Mangat PK, Garrett-Mayer E, Meric-Bernstam F, Pisick E, Alese OB, Reynolds CM, Thota R, Vaccaro GM, von Mehren M, Arend RC, Chiu VK, Duvivier HL, Gold PJ, Hack K, Marr AS, Winer A, Grantham GN, Hinshaw DC, Gregory A, Halabi S, Schilsky RL. Nivolumab Plus Ipilimumab in Patients With Solid Tumors With ATM Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2023 Sep;7:e2300279. doi: 10.1200/PO.23.00279.
- Duvivier HL, Rothe M, Mangat PK, Garrett-Mayer E, Ahn ER, Al Baghdadi T, Alva AS, Dublis SA, Cannon TL, Calfa CJ, Li R, Behl D, Chiu VK, Gold PJ, Marr AS, Mileham KF, Powell SF, Rodon J, Thota R, Grantham GN, Gregory A, Hinshaw DC, Halabi S, Schilsky RL. Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study. J Clin Oncol. 2023 Nov 20;41(33):5140-5150. doi: 10.1200/JCO.23.00702. Epub 2023 Aug 10.
- Mangat PK, Garrett-Mayer E, Perez JK, Schilsky RL. The Targeted Agent and Profiling Utilization Registry Study: A pragmatic clinical trial. Clin Trials. 2023 Dec;20(6):699-707. doi: 10.1177/17407745231182013. Epub 2023 Jul 25.
- Ganti AK, Rothe M, Mangat PK, Garrett-Mayer E, Dib EG, Duvivier HL, Ahn ER, Behl D, Borghaei H, Balmanoukian AS, Gaba A, Li R, Osei-Boateng K, Thota R, Grantham GN, Gregory A, Halabi S, Schilsky RL. Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2023 Jun;7:e2300041. doi: 10.1200/PO.23.00041.
- Ahn ER, Rothe M, Mangat PK, Garrett-Mayer E, Ali-Ahmad HM, Chan J, Maitland ML, Patel SR, Reese Z, Balmanoukian AS, Drescher CW, Li R, Tsimberidou AM, Leath CA 3rd, O'Lone R, Grantham GN, Halabi S, Schilsky RL. Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With ERBB2/3 Amplification, Overexpression, or Mutation: Results From the TAPUR Study. JCO Precis Oncol. 2023 Apr;7:e2200609. doi: 10.1200/PO.22.00609.
- Yang ES, Halabi S, Rothe M, Garrett-Mayer E, Mangat PK, Pisick E, Dib E, Burgess EF, Zakem M, Rohatgi N, Bilen MA, O'Lone R, Grantham GN, Schilsky RL. Olaparib in Patients With Metastatic Prostate Cancer With BRCA1/2 Mutation: Results From the TAPUR Study. JCO Precis Oncol. 2023 Feb;7:e2200505. doi: 10.1200/PO.22.00505.
- Carrizosa DR, Rothe M, Mangat PK, Garrett-Mayer E, Behl D, Adesunloye B, Pisick E, Beekman KW, Dotan E, Akce M, Alese OB, Sahai V, Klute KA, Aragon-Ching JB, Cooper KA, Thota R, Meric-Bernstam F, Hosein PJ, Maestas EC, Moyers JT, Powell S, Zhao S, Hobbs E, Rueter J, Sohal DPS, Taylor MA, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Olaparib in Patients With Solid Tumors With ATM Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2026 Jan;10:e2500716. doi: 10.1200/PO-25-00716. Epub 2026 Jan 15.
- Al Baghdadi T, Rothe M, Mangat PK, Garrett-Mayer E, Crysler OV, Mileham KF, Farrington LC, Adesunloye B, Dublis SA, Astsaturov I, Calfa CJ, Bleeker J, Khalil M, Thota R, Cannon TL, Alese OB, Gold PJ, Hafez N, Baron AD, Meric-Bernstam F, Hobbs E, Marr AS, Rueter J, Tawfik B, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Olaparib in Patients With Solid Tumors With BRCA1/2 Alterations: Results From The Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2025 Oct;9:e2500649. doi: 10.1200/PO-25-00649. Epub 2025 Oct 16.
- Cobain EF, Rothe M, Garrett-Mayer E, Cannon TL, Chan JK, Mileham KF, Adesunloye B, Calfa CJ, Alese OB, Butler KY, Dib EG, Pisick E, Bell M, Klute KA, Mehmi I, Meric-Bernstam F, Mangat PK, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Nivolumab Plus Ipilimumab in Patients With Solid Tumors With High Tumor Mutation Burden: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2026 Apr;10(4):e2501205. doi: 10.1200/PO-25-01205. Epub 2026 Apr 30.
- Pisick E, Rothe M, Garrett-Mayer E, Srkalovic G, Chan JK, Calfa CJ, Leath CA 3rd, Marr AS, Gold PJ, Crane EK, Moyers JT, Yost Butler K, Gaba A, Thota R, Harnden KK, Alese OB, Jain A, Rueter J, Gill S, George TJ, Frimer M, Kayali F, Mangat PK, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Temsirolimus in Patients With Solid Tumors With PIK3CA Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2026 Apr;10(4):e2500985. doi: 10.1200/PO-25-00985. Epub 2026 Apr 22.
- Veljovich DS, Rothe M, Garrett-Mayer E, Ali-Ahmad HM, Naumann RW, Siedel J, Chan JK, Gregory A, Pisick E, Adesunloye B, Arend RC, Bell M, Frimer M, Tawfik B, Thota R, Tsimberidou AM, Mangat PK, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Palbociclib in Patients With Ovarian Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2026 Jul;10(7):e2600456. doi: 10.1200/PO-26-00456. Epub 2026 Jul 15.
- Diamond-Rossi SA, Rothe M, Garrett-Mayer E, Pisick E, Bleeker J, Ganti AK, Meric-Bernstam F, Moyers JT, Nair SG, Kadakia KC, Rohatgi N, Sahai V, Vijayvergia N, Gold PJ, Sharma MR, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Cobimetinib + Vemurafenib in Patients With BRAF V600E-Mutant Papillary Thyroid and Biliary Tract Cancers: Results From the TAPUR Study. JCO Precis Oncol. 2026 Oct;10(10):e2600703. doi: 10.1200/PO-26-00703. Epub 2026 Oct 16.
- Srkalovic G, Rothe M, Garrett-Mayer E, Mileham KF, Adesunloye B, Pisick E, Leath CA 3rd, Colocci N, Chen MD, Meric-Bernstam F, Marr AS, Alese OB, Powell S, Rueter J, Benyounes A, Pontious C, Lewis MA, Thomas GW, Kier Y, Calfa CJ, von Mehren M, Acoba JD, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Sunitinib in Patients With Various Solid Tumors With FGFR1/2 Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2026 Oct;10(10):e2600454. doi: 10.1200/PO-26-00454. Epub 2026 Oct 7.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimé)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies vasculaires
- Maladies cardiovasculaires
- Maladies du système immunitaire
- Tumeurs par type histologique
- Maladies hématologiques
- Maladies lymphatiques
- Troubles lymphoprolifératifs
- Troubles immunoprolifératifs
- Lymphome
- Tumeurs, plasmocyte
- Troubles hémostatiques
- Paraprotéinémies
- Troubles des protéines sanguines
- Troubles hémorragiques
- Maladies hémiques et lymphatiques
- Tumeurs
- Myélome multiple
- Lymphome non hodgkinien
- Acides aminés, peptides et protéines
- Protéines
- Composés de soufre
- Produits chimiques organiques
- Composés hétérocycliques, 1 anneau
- Composés hétérocycliques
- Composés hétérocycliques, 2 anneaux
- Composés hétérocycliques, anneau fusionné
- Azoles
- Amides
- Indoles
- Anticorps, monoclonal, humanisé
- Anticorps, monoclonal
- Anticorps
- Immunoglobulines
- Immunoprotéines
- Protéines sanguines
- Globulines sériques
- Globulines
- Pyrroles
- Sulfonamides
- Sulfones
- Trastuzumab
- Sunitinib
- Nivolumab
- Ipilimumab
- Vémurafénib
- abemaciclib
- pertuzumab
- dabrafenib
- trametinib
- atézolizumab
- olaparib
- talazoparib
- cobimétinib
- tucatinib
- futibatinib
Autres numéros d'identification d'étude
- Pro00014171
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .